Biogen and partner Eisai Co Ltd are ending two late-stage trials testing the exp...
TOKYO/BENGALURU - Biogen and partner Eisai Co Ltd are ending two late-stage trials testing the experimental Alzheimer’s drug aducanumab, marking the latest setback for an industry racing to develop treatments for the memory-robbing disease.
Analysts expect the successful development of a treatment for Alzheimer’s, which affects about 5.7 million Americans, to virtually guarantee multi-billion dollar annual sales, but experimental treatments have had a dismal track record with more than 100 failures. The decision to discontinue the trials was made after an independent data monitoring committee reported the drug was unlikely to be successful, the companies said. The recommendation was not based on safety concerns, they added.
Investors have long been skeptical of Biogen’s Alzheimer drug pipeline and the company has been making acquisitions to diversify its potential future treatments.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Biogen's stock plummets after phase 3 trial of Alzheimer's treatment discontinuedShares of Biogen Inc. plummeted 26% toward a near 3-year low in premarket trade Thursday, after the biotechnology company and Japan's Eisai Co. Ltd. said...
Weiterlesen »
Biogen shares plunge more than 25% after ending trial for Alzheimer's drug Aducanumab
Weiterlesen »
Here are the biggest analyst calls of the day: Biogen, Apple, Micron, & moreHere are the biggest calls on Wall Street on Thursday
Weiterlesen »
Stocks making the biggest moves premarket: Biogen, Boeing, Walmart, Apple, Clorox & moreSome of the names on the move ahead of the open.
Weiterlesen »
Biogen is crashing after scrapping its late-stage Alzheimer's drug trialsBiogen shares crashed more than 25% in pre-market trading after discontinuing two late-stage Alzheimer's drug trials with Eisai.
Weiterlesen »
Stocks inch higher, led by AppleStocks fell at the open after the Fed’s latest policy announcement sparked worries about the U.S. economy while shares of Biogen dragged down the health care sector.
Weiterlesen »
Biogen is crashing after scrapping its late-stage Alzheimer's drug trialsBiogen shares crashed more than 25% in pre-market trading after discontinuing two late-stage Alzheimer's drug trials with Eisai.
Weiterlesen »
Biogen shares plunge more than 25% after ending trial for Alzheimer's drug Aducanumab
Weiterlesen »
Biogen's stock plummets after phase 3 trial of Alzheimer's treatment discontinuedShares of Biogen Inc. plummeted 26% toward a near 3-year low in premarket trade Thursday, after the biotechnology company and Japan's Eisai Co. Ltd. said...
Weiterlesen »